Insider Sale: Director at $CLMT Sells 100,000 Shares

Director Jennifer Straumins sold 100,000 shares of $CLMT on 06-05-2025 for approximately $1.32 million, representing 8.4% of their holdings, leaving them with 1,084,589 shares. Over the past six months, $CLMT insiders have executed 10 sales and one purchase, with Straumins, Daniel Sheets, and Stephen Mawer primarily selling shares; institutional investors have shown decreased positions, and UBS issued a "Sell" rating on the stock in February.

Analysis

Calumet ($CLMT) has experienced significant insider selling activity, underscored by Director Jennifer Straumins' sale of 100,000 shares on June 5, 2025, for an estimated $1.317 million, representing 8.4% of her holdings in that class of stock. This transaction is part of a wider trend observed over the past six months, during which $CLMT insiders conducted 10 sales and only one purchase. Notably, Straumins, Daniel Sheets, and Stephen Mawer were key sellers, liquidating shares worth $2.13 million, $554,200, and $127,230 respectively, while the sole purchase by EVP-CFO David Lunin amounted to a modest $32,625. This pronounced selling pressure from multiple insiders suggests a cautious internal outlook. Further corroborating this sentiment, institutional activity in the most recent quarter showed no new investors adding $CLMT shares, and one firm, IFP ADVISORS, INC, divested its entire position. Compounding these observations, UBS issued a "Sell" rating on $CLMT in February 2025, with no counteracting buy ratings reported recently. The confluence of substantial insider divestitures, waning institutional interest, and negative analyst coverage points towards a challenging near-term outlook for the stock.

Key Decisions for Investors

• Investors should view the consistent and significant insider selling at $CLMT, including the recent director's sale, as a strong cautionary signal.
• The absence of new institutional buying, coupled with a complete position exit by one firm and a "Sell" rating from UBS, suggests a need for heightened scrutiny of $CLMT's fundamentals and risk profile.
• Consider re-evaluating existing long positions or deferring new investments in $CLMT pending positive catalysts or a reversal in insider and institutional sentiment.